Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06462183 · ClinicalTrials.gov registry record · Phase 1

Study of Safety and Efficacy of RGT-61159 in Adults With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC)

A Phase 1 study of Colorectal Cancer and Adenoid Cystic Carcinoma, sponsored by Rgenta Therapeutics.

Recruiting
Registry status
Phase 1
Development phase
105
Enrollment target
10
Study locations

NCT06462183 is a Phase 1 study of Colorectal Cancer and Adenoid Cystic Carcinoma that is actively recruiting participants, run by Rgenta Therapeutics. The registered enrollment target is 105 participants, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (93% lower). The trial reports 10 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06462183, a Phase 1 study of Colorectal Cancer and Adenoid Cystic Carcinoma, is actively recruiting participants, sponsored by Rgenta Therapeutics.

RECRUITING
Registry status
Phase 1
Development phase
105 participants
Enrollment target
10
Study locations

Study Summary

Phase 1 study to evaluate safety, tolerability and anti-tumor activity of RGT-61159 in patients with ACC or CRC

Conditions Studied

Colorectal Cancer Adenoid Cystic Carcinoma

Interventions

  • DRUG RGT-61159

Study Locations (10)

New York

  • Laura & Isaac Perlmutter Cancer Center at NYU Langone Health - New York
  • Memorial Sloan Kettering Cancer Center - New York

Ontario

  • Ottawa Hospital Cancer Centre - Ottawa
  • Princess Margaret Cancer Center - Toronto

Massachusetts

  • Dana-Farber Cancer Institute - Boston

Michigan

  • University of Michigan - Ann Arbor

Missouri

  • Washington University School of Medicine - St Louis

Texas

  • MD Anderson Cancer Center - Houston

Virginia

  • Next Oncology VA - Fairfax

Washington

  • Fred Hutchinson Cancer Center - Seattle

Trial Details

FieldValue
Enrollment Target 105 participants
Start Date 2024-08-19
Est. Completion 2027-06
Phase Phase 1

Sponsor

Rgenta Therapeutics

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06462183

The ClinicalTrials.gov registry entry for NCT06462183 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 105 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (93% lower). The listed sponsor is Rgenta Therapeutics, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 1 intervention - of which RGT-61159 is the first listed.

NCT06462183 reports 10 study locations spanning 8 distinct geographic areas - top geographies include New York, Ontario, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT06462183 about?

NCT06462183 is a clinical study titled "Study of Safety and Efficacy of RGT-61159 in Adults With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC)". Phase 1 study to evaluate safety, tolerability and anti-tumor activity of RGT-61159 in patients with ACC or CRC

What is the current status of trial NCT06462183?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 105 participants. The study started on 2024-08-19. Estimated completion is 2027-06.

What conditions does trial NCT06462183 study?

This clinical trial studies the following conditions: Colorectal Cancer, Adenoid Cystic Carcinoma.

What interventions are being tested in trial NCT06462183?

The interventions under investigation include: RGT-61159 (DRUG).

Who is sponsoring clinical trial NCT06462183?

This trial is sponsored by Rgenta Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06462183 being conducted?

This trial has 10 study locations across Massachusetts, Michigan, Missouri, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Colorectal Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Colorectal Cancer

All registered trials for this condition

Adenoid Cystic Carcinoma

All registered trials for this condition

Massachusetts

All trials with a study site in Massachusetts

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.